Research programme: COVID-2019 therapeutics - Syntekabio
Latest Information Update: 15 Apr 2024
At a glance
- Originator Syntekabio
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research COVID 2019 infections